Breaking News

Eisai, BMS Enter Global Anticancer ADC Alliance

BMS to pay as much as $2.45B to co-develop Eisai’s MORAb-202

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eisai Co., Ltd. and Bristol-Myers Squibb Co. entered an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).   MORAb-202 is Eisai’s first ADC and combines Eisai’s in house developed anti-folate receptor alpha (FRalpha) antibody, and anticancer agent eribulin. It’s a potential best-in-class FR alpha ADC with a favorable pharmacology profile and demonstrated single agent activity in patients...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters